ID: ALA347211

Max Phase: Preclinical

Molecular Formula: C25H18N4O5

Molecular Weight: 454.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1[nH]c(-c2ccc3c(n2)C(=O)C(NC(C)=O)=CC3=O)c2nc3ccccc3c-2c1C

Standard InChI:  InChI=1S/C25H18N4O5/c1-11-19-13-6-4-5-7-15(13)27-23(19)22(29-20(11)25(33)34-3)16-9-8-14-18(31)10-17(26-12(2)30)24(32)21(14)28-16/h4-10,29H,1-3H3,(H,26,30)

Standard InChI Key:  PBXFGJKXQNGNJF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 454.44

Molecular Weight (Monoisotopic): 454.1277

AlogP: 3.22

#Rotatable Bonds: 3

Polar Surface Area: 131.11

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.73

CX Basic pKa: 3.04

CX LogP: 2.33

CX LogD: 2.19

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.45

Np Likeness Score: -0.05

References

1. Behforouz M, Cai W, Stocksdale MG, Lucas JS, Jung JY, Briere D, Wang A, Katen KS, Behforouz NC..  (2003)  Novel lavendamycin analogues as potent HIV-reverse transcriptase inhibitors: synthesis and evaluation of anti-reverse transcriptase activity of amide and ester analogues of lavendamycin.,  46  (26): [PMID:14667230] [10.1021/jm0304414]

2. Hassani M, Cai W, Holley DC, Lineswala JP, Maharjan BR, Ebrahimian GR, Seradj H, Stocksdale MG, Mohammadi F, Marvin CC, Gerdes JM, Beall HD, Behforouz M..  (2005)  Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.,  48  (24): [PMID:16302813] [10.1021/jm050758z]

3. Behforouz M, Cai W, Mohammadi F, Stocksdale MG, Gu Z, Ahmadian M, Baty DE, Etling MR, Al-Anzi CH, Swiftney TM, Tanzer LR, Merriman RL, Behforouz NC..  (2007)  Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones.,  15  (1): [PMID:17035024] [10.1016/j.bmc.2006.09.039]

4. Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H..  (2009)  Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.,  17  (2): [PMID:19112024] [10.1016/j.bmc.2008.11.075]

5. Cai W, Hassani M, Karki R, Walter ED, Koelsch KH, Seradj H, Lineswala JP, Mirzaei H, York JS, Olang F, Sedighi M, Lucas JS, Eads TJ, Rose AS, Charkhzarrin S, Hermann NG, Beall HD, Behforouz M..  (2010)  Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.,  18  (5): [PMID:20149966] [10.1016/j.bmc.2010.01.037]

Source

Source(1):

• Scientific Literature